Traws Pharma, Inc.

Stage 4 · Declining · week 27

As of Oct 22, 2026, Traws Pharma is in Stage 4, the downtrend phase, now in week 27 (since Apr 13, 2026). It closed at $0.37, 86.9% below its 52-week high and below its 200-day average, which is falling.

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. More about the company

$0.37

+0.00% today

$5.6M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is TRAW early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 15w

S1 14w

S4 30w

S4 20w

S4 28w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 4w → S4 15w → S1 14w → S2 4w → S3 3w → S4 30w → S1 10w → S4 20w → S1 4w → S4 3w → S1 9w → S2 5w → S3 8w → S4 4w → S2 3w → S1 1w → S4 28w current

Total tracked: 165 weeks across 17 stage runs.

TRAW among Biotechnology498th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…498	TRAWTraws Pharma, Inc.	Stage 4 · wk 27	8	−26.0%

vs 52W High

-86.9%

$0.37 lo$2.82 hi

86.9% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 27

1w13w26w

Week 27, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-69.2%

200 DMA: $1.20 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.09x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-26.0%

-24.5%

-69.7%

YTD

-72.2%

-87.6%

Scan Membership

Breakout Watch

Latest: 2024-04-08

4 appearances in last 60 days. First seen: 2020-07-09.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 27 · Vol 0.09x

2026-10-21S4

Wk 27 · Vol 0.12x

2026-10-20S4

Wk 27 · Vol 0.13x

2026-10-19S4

Wk 27 · Vol 0.14x

2026-10-16S4

Wk 27 · Vol 0.37x

2026-10-15S4

Wk 26 · Vol 0.05x

2026-10-14S4

Wk 26 · Vol 0.21x

2026-10-13S4

Wk 26 · Vol 0.13x

2026-10-12S4

Wk 26 · Vol 0.25x

2026-10-09S4

Wk 26 · Vol 0.99x

2026-10-08S4

Wk 25 · Vol 0.29x

2026-10-07S4

Wk 25 · Vol 0.32x

Moving averages & range

50 DMA

$0.52

200 DMA

$1.20

52W High

$2.82

52W Low

$0.37

5D Low

$0.37

Resistance levels (recent highs)

20d High

$0.63

60d High

$0.63

120d High

$2.18

250d High

$2.82

Next resistance

+70.3%

to 20d High

ROE

-433.4%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 3.3

Traws Pharma: quick answers

What stage is Traws Pharma in?

As of Oct 22, 2026, Traws Pharma (TRAW) is in Stage 4, the downtrend phase. It entered Stage 4 on Apr 13, 2026 and is in week 27. What the four stages mean

Is Traws Pharma in an uptrend?

No. Traws Pharma is in a Stage 4 downtrend. It trades 69.2% below its 200-day average, which is falling.

How far is Traws Pharma from its 52-week high?

Traws Pharma closed at $0.37 on Oct 22, 2026, 86.9% below its 52-week high of $2.82. Its 52-week low is $0.37.

How has Traws Pharma performed over the past year?

As of Oct 22, 2026, Traws Pharma is down 87.6% over the past year and down 72.2% so far in 2026.

Which sector and industry is Traws Pharma in?

Traws Pharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.